Research programme: RNase H inhibitors - Merck
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co
- Class Naphthyridines
- Mechanism of Action Ribonuclease H inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 20 Aug 2009 Antimicrobial data presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
- 11 Feb 2009 Preclinical trials in HIV-1 infections in USA (unspecified route)